Halozyme Therapeutics, Inc. (HALO) News
Filter HALO News Items
HALO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
HALO News Highlights
- For HALO, its 30 day story count is now at 17.
- Over the past 23 days, the trend for HALO's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
- The most mentioned tickers in articles about HALO are BEAT, SUN and MS.
Latest HALO News From Around the Web
Below are the latest news stories about Halozyme Therapeutics Inc that investors may wish to consider to help them evaluate HALO as an investment opportunity.
Halozyme''s Q4 Earnings Beat Consensus Despite Lower Product Sales Hit Topline GrowthHalozyme Therapeutics Inc (NASDAQ: HALO ) reported Q4 revenue of $102 million compared to $121.7 million a year ago, beating the consensus of $100.32 million. The decrease was primarily driven by a decline in revenue under collaboration agreement and product sales, partially offset by an increase in royalty revenue attributable to subcutaneous Darzalex (daratumumab). Revenue for Q4 included $62.6 million in royalties. Adjusted EPS of $0.42 beat Full story available on Benzinga.com |
Halozyme (HALO) Q4 Earnings Top, Royalties Drive RevenuesHalozyme (HALO) fourth-quarter earnings and sales beat estimates. The company expects royalty revenues to grow by approximately 50% in 2022. |
Halozyme Therapeutics, Inc. 2021 Q4 - Results - Earnings Call PresentationNo summary available. |
Halozyme Therapeutics, Inc.''s (HALO) CEO Helen Torley On Q4 2021 Results - Earnings Call TranscriptNo summary available. |
Halozyme Therapeutics Non-GAAP EPS of $0.42 beats by $0.01, revenue of $102M beats by $2.31MHalozyme Therapeutics press release (HALO): Q4 Non-GAAP EPS of $0.42 beats by $0.01.Revenue of $102M (-16.2% Y/Y) beats by $2.31M.2022 Revenue Guidance of $530 to $560 |
Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Surpass EstimatesHalozyme Therapeutics (HALO) delivered earnings and revenue surprises of 5% and 5.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
HALOZYME REPORTS FOURTH QUARTER 2021 AND FULL YEAR RESULTSHalozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided an update on its recent corporate activities and outlook. |
Halozyme Therapeutics Q4 2021 Earnings PreviewHalozyme Therapeutics (NASDAQ:HALO) is scheduled to announce Q4 earnings results on Tuesday, February 22nd, after market close. The consensus EPS Estimate is $0.41 and the consensus Revenue Estimate is $99.69M (-18.1% Y/Y). Over the last 2 years, HALO has beaten EPS estimates 50% of the time and has beaten revenue... |
Analysts Estimate Halozyme Therapeutics (HALO) to Report a Decline in Earnings: What to Look Out forHalozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
HALOZYME TO HOST FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS WEBCAST AND CONFERENCE CALLHalozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the fourth quarter 2021 on Tuesday, February 22 at 4:30 p.m. ET / 1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On the same date, Halozyme will release financial results for the fourth quarter and year ended December 31, 2021, following the close of trading. |